Recent Finacing
Recent Raise
Prelude Therapeutics is a clinical-stage precision oncology company that discovers and develops small-molecule PRMT5 and MCL1 inhibitors, advancing multiple candidates (PRT543, PRT811, PRT1419) in Phase 1 trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Prelude Therapeutics.
